HIT! High Impact Clinical Trials 3 - In IgA Nephropathy

29 Mar 2026 2:10 p.m. 3:10 p.m.

Main Hall

Sydney Tang Chair Hong Kong, China

Time	Session

2:10 p.m. 2:22 p.m.	EFFICACY AND SAFETY RESULTS OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY ON SODIUM‚ÄÌGLUCOSE CO-TRANSPORTER 2 INHIBITORS: PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER TRIAL (ASSIST) HiddoLambers Heerspink Speaker Netherlands
2:22 p.m. 2:34 p.m.	EFFICACY AND SAFETY OF A TARGETED-RELEASE FORMULATION OF BUDESONIDE (HR19042 CAPSULES) IN PATIENTS WITH PRIMARY IGA NEPHROPATHY: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 2/3 TRIAL XiaobingYang Speaker China
2:34 p.m. 2:46 p.m.	EVALUATING THE EFFECT OF SPARSENTAN VS IRBESARTAN ON URINE INFLAMMATORY AND PROFIBROTIC BIOMARKERS IN THE PHASE 3 PROTECT TRIAL OF PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY
2:46 p.m. 2:58 p.m.	EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN): FINAL 24-MONTH RESULTS FROM THE PHASE III APPLAUSE-IGAN STUDY VladoPerkovic Speaker Australia